Eli Lilly and Company announced today it will discontinue development of tabalumab­ — being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) — due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns

Read more here:
Eli Lilly to discontinue development of tabalumab due to insufficient efficacy in Phase 3 Lupus trials